Device Trial Radar · NCT05154448
Double Arm Pivotal Study to Evaluate the Neurolyser XR for the Treatment of Chronic Low Back Pain
Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
May 16, 2022
Primary completion
Apr 16, 2024
Study completion Apr 16, 2024
Sponsor
- Lead sponsor
- FUSMobile Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 13, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double arm pivotal study to evaluate the Neurolyser XR as a non-invasive treatment of axial chronic low back pain
Conditions
- Facet Syndrome of Lumbar Spine
Interventions
Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)Device
Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
Sham procedureOther
Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy
Primary outcomes
What the sponsor says the trial is designed to measure.
- NRSTime frame: Base line, 2 days 1, 2 & 4 weeks, 3 & 6 months after procedure
- Procedure and Device Safety up to six months post procedureTime frame: 6 months after procedure
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Stamford Hospital
Stamford, Connecticut
Mayo University Jacksonville
Jacksonville, Florida
Univ of Miami Rehabilitation Medicine
Miami, Florida
7 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.